Amneal Pharmaceuticals
440 U.S. Highway 22 East
Suite 104
Bridgewater
New Jersey
08807
United States
Tel: 908-947-3120
Fax: 908-947-4146
Website: http://www.amneal.com/
273 articles about Amneal Pharmaceuticals
-
Amneal to Report First Quarter 2020 Results on May 11, 2020
4/24/2020
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2020 financial results on Monday, May 11, 2020, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on May 11, 2020. The financial results and live webcast will be accessible through the Investor Relations section of the Compan
-
Amneal Launches Generic Butrans® Following ANDA Approval by FDA
4/16/2020
Amneal Launches Generic Butrans ® Following ANDA Approval by FDA
-
Amneal Pharmaceuticals Moving to a Virtual Meeting Format for 2020 Annual Meeting of Stockholders
4/15/2020
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) will be a virtual meeting instead of an in-person meeting. This change is in response to the ongoing COVID-19 pandemic and is intended to protect the health and safety of Amneal’s stockholders and employees. The Annual Meeting will be held Tuesday, May 5, 2020 a
-
State of Texas and Senator Bryan Hughes Secure a Donation of Hydroxychloroquine Sulfate from Amneal Pharmaceuticals for Texas Patients
3/26/2020
Amneal Pharmaceuticals, Inc., one of the largest U.S.-based generics manufacturers, and the State of Texas announced that they are responding to the national COVID-19 health emergency.
-
Amneal Accelerates Distribution and Production of Hydroxychloroquine Sulfate to Meet Potential Needs of COVID-19 Patients Nationwide
3/20/2020
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”), one of the largest U.S.-based generics manufacturers, today announced that it is responding to the national COVID-19 health emergency by building on its existing supply of hydroxychloroquine sulfate.
-
Amneal Pharmaceuticals Appoints Tasos Konidaris as Senior Vice President, Chief Financial Officer
3/11/2020
Amneal Pharmaceuticals, Inc. announced it has appointed Tasos Konidaris as Senior Vice President, Chief Financial Officer, effective March 12, 2020.
-
Amneal Reports Fourth Quarter and Full Year 2019 Financial Results
2/26/2020
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the fourth quarter and full year ended December 31, 2019.
-
Amneal to Report Fourth Quarter and Full Year 2019 Results on February 26, 2020
1/24/2020
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) announced today that the Company will release its fourth quarter and full year 2019 financial results on Wednesday, February 26, 2020, prior to the open of the U.S. financial markets.
-
Amneal Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
12/26/2019
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will present at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 15, 2020.
-
Amneal Appoints Jeff George, John Kiely and Shlomo Yanai to Board of Directors
12/16/2019
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that Jeff George, John Kiely and Shlomo Yanai have been appointed to the Company’s Board of Directors, effective as of December 14, 2019.
-
Amneal Receives Abbreviated New Drug Application Approval for EluRyng™, the First Generic NuvaRing®
12/12/2019
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for EluRyng™ (etonogestrel/ethinyl estradiol vaginal ring), the first generic version of NuvaRing®.
-
Amneal to Acquire Majority Interest in AvKARE, Enhancing Access to Growing Federal Healthcare Market
12/10/2019
Amneal Pharmaceuticals, Inc. and AvKARE Inc. announced they have entered into a definitive agreement under which Amneal will acquire a 65.1% majority interest in AvKARE and its related affiliate doing business as R&S Northeast for an implied enterprise value of $340 million.
-
Amneal Announces the Approval and Launch of Generic Carafate®
12/3/2019
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received final U.S. Food and Drug Administration approval on its Abbreviated New Drug Application for a generic version of Carafate® (sucralfate) Oral Suspension, 1 g/10 ml.
-
Amneal Announces the Approval and Launch of Generic Revatio® for Oral Suspension and Generic Amicar® Tablets
12/2/2019
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received final U.S. Food and Drug Administration (“FDA”) approval on its Abbreviated New Drug Applications (“ANDA”) for generic versions of Revatio® (sildenafil citrate) for Oral Suspension 10 mg/ml and Amicar® (aminocaproic acid) Tablets USP, 500 mg.
-
Following Civil Settlements, Opioid Drugmakers and Distributors Could Face Criminal Charges
11/27/2019
The companies are facing questions in a criminal probe regarding their marketing distribution practices related to the sale of opioids. -
Amneal Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference
11/26/2019
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that management will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference in New York on Tuesday, December 3, 2019 at 10:00 a.m. Eastern Time.
-
Amneal Reports Third Quarter 2019 Financial Results
11/6/2019
Amneal Pharmaceuticals, Inc. announced its results for the third quarter ended September 30, 2019.
-
Amneal Enters into a Licensing Agreement with Kashiv BioSciences, LLC to Develop and Commercialize K127 for the Treatment of Myasthenia Gravis
11/6/2019
Expands Amneal’s Central Nervous System (CNS) Focused Development Pipeline with Orphan Drug
-
Amneal to Report Third Quarter 2019 Results on November 6, 2019
10/9/2019
The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on November 6, 2019.
-
BioSpace scanned the WARN (Worker Adjustment and Retraining Notification) notices across the country and compiled a small list of recent layoffs across the industry.